Burning mouth syndrome responsive to pramipexol

A 68-year-old woman reported daily continuous burning feeling on the lateral and anterior site of her tongue and lower lip for 3 years. The burning was of moderate intensity (7 on a 10-point visual analogical scale), worsening by the end of the afternoon. She reported important improvement when speaking and moving the lower lip, as well as when drinking cold water. She didn’t report any worsening factor associated with worsening of the burning. She noticed change in her taste sense, with lower tolerance to heavy meals and increased burning after acid meals. She did not complain of xerostomia and therefore the salivary flow rate was not measured. She denied other medical antecedents or use of medication.

Over the past 3 years, before seeking care with us, the patient previously consulted four gastroenterologists. She was submitted to a gastroscopy and Helicobacter pylori infection was found. She had no improvement of the burning sensation after proper treatment (Table 1).

The patient also had consulted five dentists. They changed her dental prosthesis twice, tried periodontal treatment and artificial saliva without meaningful results.

The intraoral inspection was normal. She used wear superior total denture and inferior removable partial denture, both in good conditions, without vertical dimension lose or instability. She had no caries or periodontal diseases in the anterior inferior teeth. Periapical and panoramic X-ray exams were performed without alterations. General physical and neurological exams were unremarkable.

Blood analysis was performed and blood routine, as well as screening for vitamin deficiencies and ferritin were within normal limits.

We established a diagnosis of refractory BMS and initiated treatment with pramipexol (0.125 mg at night—see discussion for reasons that motivated the choice). Follow-up information was obtained prospectively using a headache calendar (measuring frequency and severity of pain, use of rescue medications, etc.) and was contrasted to the baseline. The information was independently reviewed by one of us (JGS). After 1 week of treatment the patient reported a 20% improvement (a decrease from seven to five on visual analogical scale) and around 25% diminution in the frequency of the symptoms. The dose was slowly increased to 0.75 mg at night. After 4 weeks of treatment, the burning symptoms disappeared. She remained symptom free for several months. She did not report side effects. Upon withdrawal of pramipexol, the symptoms relapsed around 6 days after, with an intensity of pain around 60% of the baseline. Since then, she has been using 0.75 mg at night, with total control of the burning sensation. The patient was followed for a year and she remains pain free, with no significant tolerability issues.

This case of BMS showed two peculiar clinical characteristics: (1) it worsened by the end of the day; (2) it improved with the movement of the tongue. The circadian fluctuation of the symptoms is a known feature of the BMS [15]; however, the relief by moving the tongue is not a notorious manifestation of this disease. Therefore, this pattern of symptoms seemed similar to what is seen in restless leg syndrome (RLS), a condition secondary due to a dopaminergic dysfunction of the central nervous system. RLS is characterized by lower limbs dysesthesias that worsen by the end of the day and improve when moving the legs [16, 17]. The prevalence of RLS in patients with headache is high, [18], however, there are no data correlating RLS with BMS.

Although the relationship between BMS and Parkinson’s disease is not universally accepted, the comorbidity has been suggested. BMS is frequent among patients with Parkinson’s disease (PD). In a study of 115 patients with PD, burning mouth happened in 24% of them, incidence prevalence 30 times greater than expected by chance only [19].

The dopaminergic and nigrostriatal pathways are important on pain modulation [20‐22]. Non-specific disturbances on the dopaminergic system have been documented in patients with BMS [8, 9]. The association of BMS with RLS and PD, besides the improvement with amisulpiride [11], point to a dopaminergic dysfunction in BMS. All these facts support our therapeutic choice for the reported case. Pramipexol is a non-ergotic dopaminergic agonist, with predilection to dopaminergic D-2 receptors [23, 24]. Our anedoctal finding should be confirmed by a pilot study, and, if positive, by clinical trials. As a cautionary note, since this is a report of a single case, we cannot exclude that the therapeutic response to pramipexol happened as a placebo effect, or merely as a coincidence.